Condition 1: End-stage renal disease. Condition 2: Thrombosis-related malfunction of tunneled-cuffed central venous catheters (TCC). End stage renal disease Other complication of vascular dialysis catheter
Conditions
Interventions
Intervention 1: Intervention group: Patients will receive oral apixaban at a dose of 2.5 mg daily for 6 months. Intervention 2: Control group: Patients will receive routine treatment in Iran. Patients
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Hemodialysis patients undergoing TCC insertion in Imam Khomeini Hospital of Urmia. being older than 18 years
Exclusion criteria
Exclusion criteria: Patients who are treated with anticoagulant or other antiplatelet drugs. Patients who have a life expectancy of less than 3 months. Patients who have abnormal coagulation tests (PTT-PT-INR) before starting the intervention. Patients with known coagulation disorders. Patients with uncontrolled hypertension. Patients who have malignancy. Patients who are pregnant. Patients who are breastfeeding. Patients with an active infectious disease. Patients with liver failure. Patients who have a history of allergy to apixaban. Patients with a history of pulmonary embolism.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Thrombosis percentage of tunneled cuffed catheters. Timepoint: At the beginning of the study and then 6 and 12 months after the catheter was placed. Method of measurement: Observing the malfunction of the catheter in dialysis, bleeding and any related complications. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKhodadad Ghaffari
Oroumia University of Medical Sciences
Outcome results
None listed